Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD63 antisense RNA 1 (CD63-AS1) is a long non-coding RNA that encodes a mitochondrial-localized, amyloid-like motif–containing microprotein referred to as CEAM. Expression of CD63-AS1 and its microprotein product has been identified in human heart tissue, particularly cardiomyocytes. CEAM is unique in that it forms protease-resistant aggregates within mitochondria and can disrupt mitochondrial bioenergetics, triggering mitochondrial stress responses. Overexpression of CEAM in animal models impairs cardiac function, but elevated expression during pressure overload-induced cardiac hypertrophy may play a protective modulatory role by dampening gene expression associated with pathological remodeling. CD63-AS1 and CEAM represent a novel class of microprotein-generating non-coding RNAs, offering new mechanistic insight into mitochondrial function and stress adaptation in the heart, but they are not established as conventional therapeutic targets.
not applicable (no drugs known to target this molecule)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD63 antisense RNA 1 (CD63-AS1).